These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 34570179)

  • 1. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.
    Stengel A; Baer C; Walter W; Meggendorfer M; Kern W; Haferlach T; Haferlach C
    Blood Adv; 2021 Nov; 5(21):4426-4434. PubMed ID: 34570179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.
    Chen D; Geyer J; Bagg A; Hasserjian R; Weinberg OK
    Int J Lab Hematol; 2024 Aug; 46(4):687-694. PubMed ID: 38665121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal cytopenias of undetermined significance: potential predictor of myeloid malignancies?
    Vobugari N; Heuston C; Lai C
    Clin Adv Hematol Oncol; 2022 Jun; 20(6):375-383. PubMed ID: 35731608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
    Fujino T
    Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid malignancies: mutations, models and management.
    Murati A; Brecqueville M; Devillier R; Mozziconacci MJ; Gelsi-Boyer V; Birnbaum D
    BMC Cancer; 2012 Jul; 12():304. PubMed ID: 22823977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [TFH lymphoma and associated clonal hematopoiesis].
    Nann D; Fend F; Quintanilla-Martinez L
    Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):144-149. PubMed ID: 37870568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Karantanos T; Gondek LP; Varadhan R; Moliterno AR; DeZern AE; Jones RJ; Jain T
    Br J Haematol; 2021 Jun; 193(6):1142-1150. PubMed ID: 34028801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genomic aberrations in myelodysplastic syndromes and related disorders].
    Makishima H
    Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.
    McClure RF; Ewalt MD; Crow J; Temple-Smolkin RL; Pullambhatla M; Sargent R; Kim AS
    J Mol Diagn; 2018 Nov; 20(6):717-737. PubMed ID: 30138727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
    Shuai W; Zuo Z; Li N; Garces S; Jelloul FZ; Ok CY; Li S; Xu J; You MJ; Wang W; Rehder C; Jabbour EJ; Patel KP; Medeiros LJ; Yin CC
    Cancer; 2023 Mar; 129(6):878-889. PubMed ID: 36583229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
    Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
    Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
    Gill H; Leung AY; Kwong YL
    Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of clonal progression leading to the development of therapy-related myeloid neoplasms.
    Guarnera L; Pascale MR; Hajrullaj H; Cristiano A; Mallegni F; Onorato A; Voso MT; Fabiani E
    Ann Hematol; 2024 Sep; 103(9):3507-3517. PubMed ID: 39031199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
    Sutandyo N; Mulyasari R; Kosasih A; Rinaldi I; Louisa M; Kevinsyah AP; Winston K
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1107-1116. PubMed ID: 35485665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predisposition and progression of myelodysplastic syndromes].
    Makishima H
    Rinsho Ketsueki; 2021; 62(4):278-288. PubMed ID: 33967153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
    Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.